EA201891780A1 - Производные сульфонамида и содержащие их фармацевтические композиции - Google Patents

Производные сульфонамида и содержащие их фармацевтические композиции

Info

Publication number
EA201891780A1
EA201891780A1 EA201891780A EA201891780A EA201891780A1 EA 201891780 A1 EA201891780 A1 EA 201891780A1 EA 201891780 A EA201891780 A EA 201891780A EA 201891780 A EA201891780 A EA 201891780A EA 201891780 A1 EA201891780 A1 EA 201891780A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
sulphonamide
pharmaceutical compositions
compounds
integrin
Prior art date
Application number
EA201891780A
Other languages
English (en)
Other versions
EA036432B1 (ru
Inventor
Минетака Токомасу
Масацугу Ногути
Мидзуки Кавахира
Кана Ивасаки
Нобухико Хайакава
Ватару Миянага
Юки Саитоу
Юи Ямаура
Аятоси Андо
Ацуси Цурута
Мисато Ногути
Original Assignee
Эа Фарма Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эа Фарма Ко., Лтд. filed Critical Эа Фарма Ко., Лтд.
Publication of EA201891780A1 publication Critical patent/EA201891780A1/ru
Publication of EA036432B1 publication Critical patent/EA036432B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Предложены соединения, обладающие ингибирующим действием на α4-интегрин. Соединения представляют собой производные сульфонамида следующей формулы (I), либо их фармацевтически приемлемые соли:где R-R, e, f, g, h, D и B означают то, что указано в описании.
EA201891780A 2016-02-05 2017-02-06 Производные сульфонамида и содержащие их фармацевтические композиции EA036432B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016021053 2016-02-05
PCT/JP2017/004278 WO2017135472A1 (ja) 2016-02-05 2017-02-06 スルホンアミド誘導体及びそれを含有する医薬組成物

Publications (2)

Publication Number Publication Date
EA201891780A1 true EA201891780A1 (ru) 2019-02-28
EA036432B1 EA036432B1 (ru) 2020-11-10

Family

ID=59500204

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891780A EA036432B1 (ru) 2016-02-05 2017-02-06 Производные сульфонамида и содержащие их фармацевтические композиции

Country Status (16)

Country Link
US (1) US10562898B2 (ru)
EP (1) EP3412660B9 (ru)
JP (1) JP6820282B2 (ru)
KR (1) KR102870086B1 (ru)
CN (1) CN108699008B (ru)
AU (1) AU2017214589B2 (ru)
CA (1) CA3013433A1 (ru)
DK (1) DK3412660T3 (ru)
EA (1) EA036432B1 (ru)
ES (1) ES2856125T3 (ru)
HU (1) HUE053354T2 (ru)
MX (1) MX381970B (ru)
PL (1) PL3412660T3 (ru)
PT (1) PT3412660T (ru)
TW (1) TWI730042B (ru)
WO (1) WO2017135472A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE277034T1 (de) 1998-10-26 2004-10-15 Univ New York State Res Found Liponsaürederivate und deren verwendung bei der behandlung von krankheiten
TWI754702B (zh) 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類
US12582809B2 (en) 2018-01-26 2026-03-24 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor
EP3810085A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
KR102630416B1 (ko) 2018-10-30 2024-02-01 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
CN114222730B (zh) * 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
MX2024004049A (es) 2021-10-05 2024-04-25 Ea Pharma Co Ltd Metodo para producir compuesto o sal farmaceuticamente aceptable del mismo.
CN120882414A (zh) 2023-04-06 2025-10-31 Ea制药株式会社 用于治疗炎症性肠病的药物组合物
CN120897744A (zh) 2023-04-06 2025-11-04 Ea制药株式会社 含有磺酰胺衍生物的自乳化组合物和自乳化药物递送系统

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU779063B2 (en) 1999-12-06 2005-01-06 F. Hoffmann-La Roche Ag 4-pyridinyl-N-acyl-L-phenylalanines
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
WO2001056994A1 (en) * 2000-02-04 2001-08-09 Biogen, Inc. Integrin antagonists
ATE497385T1 (de) 2000-08-18 2011-02-15 Ajinomoto Kk Neue phenylalanin-derivate
EP1477482B1 (en) 2002-02-20 2010-04-14 Ajinomoto Co., Inc. Novel phenylalanine derivative
JP4233353B2 (ja) 2002-02-27 2009-03-04 田辺三菱製薬株式会社 医薬組成物
AU2004251750A1 (en) * 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
EP1700850B1 (en) 2003-12-22 2015-07-15 Ajinomoto Co., Inc. Phenylalanine derivative
WO2005077915A1 (en) 2004-02-10 2005-08-25 Janssen Pharmaceutica, N.V. Pyridazinones as antagonists of a4 integrins
EP1735000A2 (en) * 2004-04-16 2006-12-27 Genentech, Inc. Method for augmenting b cell depletion
JP5231215B2 (ja) 2005-05-20 2013-07-10 イーラン ファーマスーティカルズ、インコーポレイテッド Ｖｌａ−４アンタゴニストとしてのイミダゾロンフェニルアラニン誘導体
CA2871464C (en) * 2012-04-24 2017-09-26 Ajinomoto Co., Inc. Sulfonamide derivatives and their use in the inhibition of .alpha.4.beta.7 integrin-dependent process
DE102013206014A1 (de) * 2013-04-05 2014-10-09 Dürr Systems GmbH Energiewandler-System und Baugruppen hierfür
ES2778200T3 (es) * 2013-10-29 2020-08-10 Ea Pharma Co Ltd Derivado de sulfonamida y su uso medicinal

Also Published As

Publication number Publication date
EP3412660B1 (en) 2020-11-18
MX2018009459A (es) 2018-09-21
KR102870086B1 (ko) 2025-10-16
WO2017135472A1 (ja) 2017-08-10
TW201733991A (zh) 2017-10-01
CN108699008A (zh) 2018-10-23
CA3013433A1 (en) 2017-08-10
ES2856125T3 (es) 2021-09-27
TWI730042B (zh) 2021-06-11
MX381970B (es) 2025-03-04
AU2017214589B2 (en) 2020-09-03
KR20180104758A (ko) 2018-09-21
US10562898B2 (en) 2020-02-18
BR112018015855A2 (pt) 2018-12-26
AU2017214589A1 (en) 2018-08-16
CN108699008B (zh) 2021-10-08
PL3412660T3 (pl) 2021-04-19
DK3412660T3 (da) 2020-11-30
PT3412660T (pt) 2021-01-13
EP3412660A4 (en) 2019-07-10
JPWO2017135472A1 (ja) 2018-11-29
EP3412660B9 (en) 2021-04-14
JP6820282B2 (ja) 2021-01-27
HUE053354T2 (hu) 2021-06-28
US20190040059A1 (en) 2019-02-07
EA036432B1 (ru) 2020-11-10
EP3412660A1 (en) 2018-12-12

Similar Documents

Publication Publication Date Title
JOP20170107B1 (ar) مشتقات سلفوناميد عطرية
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
EA201991700A1 (ru) Селективные ингибиторы jak1
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201691302A1 (ru) Новые гетероциклические соединения
EA201500875A1 (ru) СОЛИ ПРОИЗВОДНЫХ 2-АМИНО-1-ГИДРОКСИЭТИЛ-8-ГИДРОКСИХИНОЛИН-2-(1Н)-ОНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
MX2016001480A (es) Formulacion de inhibidores de syk.
EA201891438A1 (ru) Кислотно-аддитивные соли производных пиперазина
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
EA202191519A1 (ru) Модуляторы trex1
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
EA201600434A1 (ru) Применение производных бензимидазолпролина
MX381970B (es) Derivado de sulfonamida y composición farmacéutica que contiene el mismo.
MX373389B (es) Derivado de sulfonamida y uso farmaceutico del mismo.
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
EA201991595A1 (ru) Активатор nrf2
EA201692270A1 (ru) Производные нафтиридиндиона
EA201891782A1 (ru) Гетероциклическое сульфонамидное производное и содержащее его лекарственное средство
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
EA201650003A1 (ru) Соединённые циклоалкилом дигетероциклические производные
EA201890616A1 (ru) Сульфонамидные соединения в качестве модуляторов потенциалуправляемых натриевых каналов

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM